Key facts
- It has raised $47.1M across 6 recorded rounds; the latest was Seed Round ($1.4M) in May 2026.
- Notable investors include Lateral Capital Management, John Lilly Strategic Insights.
- Reprise Biomedical has filed 8 Form Ds with the SEC since 2019, most recently Jul 2025 ($6.4M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Reprise Biomedical
Funding rounds
6 roundsAbout Reprise Biomedical
Developer of biological medical products designed to support cellular integration. The company uses a perfusion decellularization process to develop a preserved native scaffold containing the appropriate strength and microenvironment for cellular integration after it is implanted in the patient's body, enabling clinicians to get the tools to treat surgical and trauma wounds and to be used in surgical soft tissue reinforcement.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2019
- Employees
- 47
- Website
- reprisebio.com/
- Ownership
- Privately Held (backing)
Reprise Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reprise Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reprise Biomedical in its N-PORT filings yet. We sweep new filings monthly.